Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): a Double-blind, Randomized, Placebo-controlled Study

Next Previous
Search
Trial Profile

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): a Double-blind, Randomized, Placebo-controlled Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary) ; Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms ReTRIACt
  • Sponsors Rare Thyroid Therapeutics

    • Most Recent Events

    • 18 Dec 2024 According to an Egetis Therapeutics media release,the company will announce an update of the status of the ReTRIACt trial which will feature presentations by Professor Edward Visser, Erasmus MC, Rotterdam, The Netherlands on the recent advances with tiratricol in monocarboxylate transporter 8 (MCT8) deficiency and Professor Aled Rees, Cardiff University, UK, on resistance to thyroid hormone beta (RTH-beta), the unmet medical need and the potential opportunity for Emcitate in this disease
    • 08 Nov 2024 According to an Egetis Therapeutics media release,the company announced In the ReTRIACt study, which is pivotal for the New Drug Application in the USA, 17 patients have been included, whereof 8 patients have completed the randomized phase.
    • 16 Oct 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top